Alopecia Drugs Market By Type (Alopecia areata, Alopecia Totalis, Alopecia Universalis) By Route of Administration (Topical, Oral, Injectable) By End-User (Hospitals and Clinics, Salons, Home Care) and By Region - Global Forecast To 2033
Alopecia Drugs market was valued at US$ 8.72 billion in 2022 and it is projected to grow US$ 14.61 billion by 2033, registering a CAGR of 4.80% during the forecast period of 2022 to 2033.
The report offers in-depth insights, revenue details, and other vital information regarding the global alopecia drugs market and the various trends, drivers, restraints, opportunities, and threats in the target market till 2026. The report also offers insightful and detailed information regarding the various key players operating in the global alopecia drugs market, and their financials, apart from strategies, acquisitions & mergers, and market footprint. The global alopecia drugs market report has been segmented on the basis of type, material, design, application, and region.
Alopecia is a hair loss condition which affects scalp of individuals. It causes clumps of hair to fall out resulting in hairless patches on scalp or other areas of the body. In some cases, individuals affected by alopecia may have thinner hair leading to unnoticeable patches of baldness, leaving short snubs called exclamation point hair. Alopecia drugs have proven useful in treating hair loss conditions to a significant extent in both males and females. The drugs are prescribed by healthcare professionals depending on the type of alopecia, age and extent of hair loss. For individuals with more than 50% hair loss on their scalp or other body parts, oral and topical medications have shown fruitful outcomes. The medications commonly used for the treatment of alopecia are specifically approved by the Food and Drug Administration (FDA). Assessment of the efficacy of a drug must be considered with care as the condition is highly unpredictable and vary in presentation, evolution, and response to treatment.
Global Alopecia Drugs Market Dynamics:
Increasing incidence of hair loss in both males and females across the globe is a key factor driving growth of the global market over the forecast period. For instance, the American Academy of Dermatology stated that around 80 million people suffered from hair loss problems in US alone in 2016. Another factor fueling global market is increasing awareness among individuals pertaining to availability of various treatments in the market, which can be attributed to the initiatives taken by several regulatory bodies such as the National Alopecia Areata Foundation (NAAF) and the American Hair Loss Association (AHLA). Rapunzel Project is an initiative by AHLA which works to prevent hair loss in chemotherapy patients. Furthermore, approval of janus kinase inhibitors (JAK) drugs with minimal side effects by FDA is other factor expected to impel growth of target market in the near future.
Report Coverage and Deliverables
However, high cost and adverse effect of drugs coupled with failure of drugs related to emotional stress are factors expected to restrain growth of the global market over the forecast period.
Introduction and development of new drugs with minimal side effects to treat alopecia can create potential revenue opportunities for target players in the global market.
Market Analysis by Alopecia Drugs Route of Administration:
On the basis of route of administration, topical segment is expected to account for major share in terms of revenue in the global market and is projected to register a CAGR of over 5% over the forecast period, owing to its easy application, high absorbability on scalp, and non-invasive nature. Topical treatment involves topical corticosteroids that are available in various forms such as lotions, gels, and liquids. Moreover, the topical segment is projected to maintain its dominant revenue contribution in the global market over the forecast period.
Furthermore, entry of AVODART for alopecia treatment in emerging economies such as Japan, South Korea, and Australia is expected to further drive market growth over the forecast period.
Limited clinical efficacy by alopecia drugs would hamper market share and revenue growth of established products over the forecast period.
Global Alopecia Dugs Market Analysis by Gender:
Male segment dominated the global alopecia drugs market in revenue terms, accounting for highest revenue share and registering a CAGR of over 4.5% during the forecast period 2017 & 2026. It is further projected to maintain its dominant revenue contribution over the forecast period, owing to higher smoking and drinking habits of men as compared to women.
The occurrence of alopecia is most common in men than in women. According to a 2014 survey by the International Society of Hair Restoration Surgery, an estimated 35 Mn men and 21 Mn women suffered from hair loss in US.
In women, the major cause of hair loss can be hormonal imbalances caused by disorders such as polycystic ovary syndrome (PCOS), which leads to androgenetic alopecia. Traction alopecia is also commonly observed in women due to the rising stress levels on hair follicles by factors such as hairstyles and changing sedentary lifestyle.
Global Market Analysis by Region:
The Americas market is expected to dominate the global alopecia drugs market in revenue terms, by accounting for largest market revenue share of over 50% in 2017 as compared to that of markets in other regions. It is further expected to maintain its dominant revenue contribution in the global alopecia drugs market over the forecast period. This can be attributed to increasing awareness about alopecia and easy availability of OTC drugs. Availability of technologically advanced healthcare infrastructure and novel therapeutic options related to alopecia treatments are other factors contributing to the highest market share.
The market in Asia Pacific is projected to register a significant growth of around 7%, which is relatively higher than that of markets in other regions. Increasing incidence of hair loss in both males and females, rising awareness levels among individuals about available treatment options and rising disposable income in emerging economies such as China, India and Singapore are factors expected to create high potential growth opportunities in the Asia Pacific market over the forecast period. Product expansion by the key players in the emerging economies is another major factor boosting growth in the Asia Pacific region. For instance, AVODART was approved for treatment of alopecia in South Korea in 2010 and in Japan in September 2015.
Moreover, markets in Latin America and Middle East & Africa are also projected to witness moderate growth over the forecast period owing to recent advancements in technology, increasing healthcare expenditures, rising initiatives by regulatory bodies and augmented healthcare facilities are expected to boost the target market.
Global Alopecia Drugs Market Segmentation:
Global alopecia drugs market segmentation by route of administration:
Global alopecia drugs market segmentation by gender:
Global alopecia drugs market segmentation, by region:
- The Americas
- Asia Pacific
- Rest of the World (ROW)
Attribute Report Details Market Size Ask For Market Size Growth Rate Ask For Growth Rate Key Companies Ask For Companies Report Coverage Revenue analysis, Competitive landscape, Key company analysis, Market Trends, Key segments, Distribution Channel, Market Dynamics, COVID-19 Impact Analysis and more… Historical Data Period 2015-2020 Base Year 2022 Forecast Period 2022-2031 Region Scope North America, Europe, Asia-Pacific, South America, Middle East & Africa Country Scope United States, Canada and Mexico, Germany, France, UK, Russia and Italy, China, Japan, Korea, India and Southeast Asia, Brazil, Argentina, Colombia etc.Saudi Arabia, UAE, Egypt, Nigeria and South Africa Revenue in US$ Mn
- Taisho Pharmaceutical Holdings Co. Ltd.
- The Himalaya Drug Company
- Johnson & Johnson Services, Inc.
- GlaxoSmithKline Plc.
- Cipla Inc.
- Reddy’s Laboratories Ltd.
- Vitabiotics Ltd.
- 1.0 Chapter 1
- 1.1 Preface
- 1.2 Assumptions
- 1.3 Abbreviations
- 2.1 Report Description
- 2.1.1 Market Definition and Scope
- 2.2 Executive Summary
- 2.2.1 Market Snapshot, By Route of Administration
- 2.2.2 Market Snapshot, By Gender
- 2.2.3 Market Snapshot, By Geography
- 3.1 Global Alopecia Drugs Market Dynamics
- 3.1.1 Drivers
- 3.1.2 Restraints
- 3.1.3 Opportunities
- 3.1.4 PEST Analysis
- 3.1.5 PORTERS Analysis
- 4.0.1 Global Alopecia Drugs Market Analysis, by Route of Administration
- 4.0.2 Overview
- 4.0.3 Segment Trends
- 4.0.4 Market Share and Forecast, and Y-o-Y Growth, 2016-2026, (US $ Million)
- 4.1 Oral
- 4.1.1 Overview
- 4.1.2 Market Share and Forecast, and Y-o-Y Growth, 2016-2026, (US $ Million)
- 4.2 Injectable
- 4.2.1 Overview
- 4.2.2 Market Share and Forecast, and Y-o-Y Growth, 2016-2026, (US $ Million)
- 4.3 Topical
- 4.3.1 Overview
- 4.3.2 Market Share and Forecast, and Y-o-Y Growth, 2016-2026, (US $ Million)
- 5.0.1 Global Alopecia Drugs Market Analysis, by Gender
- 5.0.2 Overview
- 5.0.3 Segment Trends
- 5.0.4 Market Share and Forecast, and Y-o-Y Growth, 2016-2026, (US $ Million)
- 5.1 Men
- 5.1.1 Overview
- 5.1.2 Market Share and Forecast, and Y-o-Y Growth, 2016-2026, (US $ Million)
- 5.2 Women
- 5.2.1 Overview
- 5.2.2 Market Share and Forecast, and Y-o-Y Growth, 2016-2026, (US $ Million)
- 6.0.1 Global Alopecia Drugs Market Analysis, by Region
- 6.0.2 Overview
- 6.0.3 Regional Trends
- 6.0.4 Market Share and Forecast, and Y-o-Y Growth, 2016-2026, (US $ Million)
- 6.1 The Americas
- 6.1.1 Overview
- 6.1.2 Country Trends
- 6.1.3 Market Share and Forecast, and Y-o-Y Growth, 2016-2026, (US $ Million)
- 6.1.4 U.S.
- 6.1.5 Canada
- 6.1.6 Rest of America
- 6.2 Europe
- 6.2.1 Overview
- 6.2.2 Country Trends
- 6.2.3 Market Share and Forecast, and Y-o-Y Growth, 2016-2026, (US $ Million)
- 6.2.4 Germany
- 6.2.5 France
- 6.2.6 Spain
- 6.2.7 U.K.
- 6.2.8 Rest of Europe
- 6.3 Asia Pacific
- 6.3.1 Overview
- 6.3.2 Country Trends
- 6.3.3 Market Share and Forecast, and Y-o-Y Growth, 2016-2026, (US $ Million)
- 6.3.4 China
- 6.3.5 India
- 6.3.6 Japan
- 6.3.7 Australia
- 6.3.8 Rest of APAC
- 6.4 Rest of the World
- 6.4.1 Overview
- 6.4.2 Market Share and Forecast, and Y-o-Y Growth, 2016-2026, (US $ Million)
- 7.0.1 Competitive Dashboard
- 7.0.2 Heat Map Analysis
- 7.0.3 Company Profiles
- 7.1 Taisho Pharmaceutical Holdings Co. Ltd.*
- 7.1.1 Company Overview
- 7.1.2 Product Portfolio
- 7.1.3 Financial Overview
- 7.1.4 Key Developments
- 7.1.5 SWOT Analysis
- 7.2 The Himalaya Drug company
- 7.3 Johnson & Johnson Services, Inc.
- 7.4 GlaxoSmithKline Plc.
- 7.5 Cipla Inc.
- 7.6 Dr. Reddy’s Laboratories Ltd.
- 7.7 MERCK
- 7.8 Vitabiotic Ltd.
- 7.9 Sun Pharmaceutical Industries Ltd.
- 8.1 About Us
- 8.2 Research Methodology
Why Choose Us
- 360 Degree Approach
- Growth Consulting
- 24/7 Research Support
- Comprehensive-Level of Customization
- Comprehensive-Level of Customization
- Competitive Intelligence
- Single-Country/ Region Intelligence
- Post-Sale Service Assistance
- Access to Lead Analysts
- Available in PDF, Excel, Word/ PPT
Request for Customization
Don't just take our word. We are trusted by these great companies!